223 related articles for article (PubMed ID: 38685841)
21. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
Li M; Sun K; Welniak LA; Murphy WJ
Expert Opin Pharmacother; 2008 Sep; 9(13):2305-16. PubMed ID: 18710355
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
25. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
[TBL] [Abstract][Full Text] [Related]
27. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic use of regulatory T cells for graft-versus-host disease.
Elias S; Rudensky AY
Br J Haematol; 2019 Oct; 187(1):25-38. PubMed ID: 31418827
[TBL] [Abstract][Full Text] [Related]
29. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
30. A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4
Ito R; Katano I; Kawai K; Yagoto M; Takahashi T; Ka Y; Ogura T; Takahashi R; Ito M
Am J Transplant; 2017 May; 17(5):1216-1228. PubMed ID: 27862942
[TBL] [Abstract][Full Text] [Related]
31. Increased splenic human CD4
Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
[TBL] [Abstract][Full Text] [Related]
32. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
33. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease.
Liu J; Anderson BE; Robert ME; McNiff JM; Emerson SG; Shlomchik WD; Shlomchik MJ
Blood; 2001 Dec; 98(12):3367-75. PubMed ID: 11719376
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.
Hippen KL; Watkins B; Tkachev V; Lemire AM; Lehnen C; Riddle MJ; Singh K; Panoskaltsis-Mortari A; Vanhove B; Tolar J; Kean LS; Blazar BR
Transplantation; 2016 Dec; 100(12):2630-2639. PubMed ID: 27861291
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
36. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
Zeiser R; Blazar BR
Blood; 2016 Jun; 127(25):3117-26. PubMed ID: 26994149
[TBL] [Abstract][Full Text] [Related]
37. Insights into the pathogenesis of GvHD: what mice can teach us about man.
Hülsdünker J; Zeiser R
Tissue Antigens; 2015 Jan; 85(1):2-9. PubMed ID: 25532439
[TBL] [Abstract][Full Text] [Related]
38. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.
Tsirigotis P; Or R; Resnick IB; Shapira MY
Immunotherapy; 2012 Apr; 4(4):407-24. PubMed ID: 22512635
[TBL] [Abstract][Full Text] [Related]
40. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
Norelli M; Camisa B; Bondanza A
Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
